OSSIO is expanding its sports medicine portfolio with the launch of the OSSIOfiber interference screw, a bio-integrative, metal-free fixation solution designed primarily for ACL reconstruction.
Built with the company’s proprietary platform technology, the implant delivers metal-like fixation strength while ultimately integrating into the patient’s native bone. The result is a restored orthopedic landscape without permanent hardware or residual implant material, helping simplify revision ACL reconstruction or other future surgeries.
The implant provides secure graft fixation with a material that is 5x stronger than traditional bio-composites, 2x stronger than PEEK and 1.5x stronger than cortical bone.
Further, OSSIO is expanding its national direct-to-patient campaign to include the KneeBar Procedure, broadening awareness of bio-integrative treatment options for patients with persistent pain caused by insufficiency fractures in the bone around the knee.
In addition, the company reached a milestone in July with the 100,000th use of an OSSIOfiber implant in clinical practice, seven years since the technology’s commercial introduction in 2019.
OSSIO is expanding its sports medicine portfolio with the launch of the OSSIOfiber interference screw, a bio-integrative, metal-free fixation solution designed primarily for ACL reconstruction.
Built with the company’s proprietary platform technology, the implant delivers metal-like fixation strength while ultimately integrating into the...
OSSIO is expanding its sports medicine portfolio with the launch of the OSSIOfiber interference screw, a bio-integrative, metal-free fixation solution designed primarily for ACL reconstruction.
Built with the company’s proprietary platform technology, the implant delivers metal-like fixation strength while ultimately integrating into the patient’s native bone. The result is a restored orthopedic landscape without permanent hardware or residual implant material, helping simplify revision ACL reconstruction or other future surgeries.
The implant provides secure graft fixation with a material that is 5x stronger than traditional bio-composites, 2x stronger than PEEK and 1.5x stronger than cortical bone.
Further, OSSIO is expanding its national direct-to-patient campaign to include the KneeBar Procedure, broadening awareness of bio-integrative treatment options for patients with persistent pain caused by insufficiency fractures in the bone around the knee.
In addition, the company reached a milestone in July with the 100,000th use of an OSSIOfiber implant in clinical practice, seven years since the technology’s commercial introduction in 2019.
Copy to clipboard 
